Lytix Biopharma: NeoLIPA hits primary endpoint - Redeye

Lytix Biopharma: NeoLIPA hits primary endpoint - Redeye

Redeye is optimistic after Lytix' announcement that the investigator-initiated phase II study NeoLIPA, which tests ruxotemitide with pembrolizumab before surgery in resectable melanoma, has met its primary endpoint of pathological complete response (pCR). We view the readout as clearly positive, as it removes the key binary risk in the share for 2026.

Länk till analysen i sin helhet: https://www.redeye.se/research/1190390/lytix-biopharma-neolipa-hits-primary-endpoint?utm_source=finwire&utm_medium=RSS